Drug · FAERS side-effect profile with label screen

Pseudoephedrine side effects: what 10,953 FDA adverse event reports show

Pseudoephedrine Hcl · 976 reaction terms · 325,783 drug–reaction co-reports · data 2026-09-14

Drug class

Not stated in label

Label matched

Pseudoephedrine Hcl (Sudogest Nasal Decongestant)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

10,953 reports · 88% serious · 3,852 with death outcome · 89% female

openFDA FAERS counts, all years, deduplication not applied

Used for

• temporarily relieves sinus congestion and pressure • temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies

FDA label, Indications and Usage

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Reporting / coding artifact 2Lab value / disease marker 7No label text to screen 31

What the badges mean

Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 936 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Swollen joint count increased	1,711	2,361.4 2,204.9–2,529.1ROR 2,798.4 · calibrated p 5e-23 ✓	1,037.5 EB05 996.8 · IC025 +9.6 3/3 methods agree	Lab value / disease marker	serious n=1,710 · 95% clinician	not reported in cached trials
Hepatic enzyme	76	2,314.4 1,655.7–3,235.1ROR 2,330.6 · calibrated p 7e-21 ✓	823.0 EB05 679.1 · IC025 +6.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=76 · 100% clinician	not reported in cached trials
Rheumatic fever	2,310	2,178.5 2,058.1–2,305.9ROR 2,760.4 · calibrated p 6e-23 ✓	1,003.5 EB05 969.6 · IC025 +9.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=2,309 · 94% clinician	not reported in cached trials
Anti-cyclic citrullinated peptide antibody positive	3,575	1,962.1 1,879.8–2,048.2ROR 2,912.3 · calibrated p 3e-23 ✓	957.7 EB05 931.7 · IC025 +9.7 3/3 methods agree	Lab value / disease marker	serious PRR 628.4 · 93% clinician	not reported in cached trials
Anti-cyclic citrullinated peptide antibody	327	1,859.6 1,598.1–2,163.9ROR 1,916.8 · calibrated p 1e-20 ✓	888.2 EB05 810.3 · IC025 +8.4 3/3 methods agree	Lab value / disease marker	serious n=327 · 94% clinician	not reported in cached trials
Lupus vulgaris	552	1,672.9 1,494.1–1,873.1ROR 1,761.6 · calibrated p 3e-20 ✓	860.8 EB05 802.1 · IC025 +8.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=552 · 96% clinician	not reported in cached trials
Rheumatoid factor positive	2,540	1,520.0 1,447.7–1,596.0ROR 1,978.6 · calibrated p 5e-21 ✓	837.2 EB05 810.2 · IC025 +9.4 3/3 methods agree	Lab value / disease marker	serious n=2,538 · 93% clinician	not reported in cached trials
Deep vein thrombosis postoperative	850	1,477.8 1,353.6–1,613.3ROR 1,602.0 · calibrated p 9e-20 ✓	814.1 EB05 769.2 · IC025 +9.0 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=850 · 93% clinician	not reported in cached trials
Pemphigus	5,214	1,395.2 1,353.3–1,438.4ROR 2,661.6 · calibrated p 1e-22 ✓	800.4 EB05 782.3 · IC025 +9.5 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 523.9 · 92% clinician	not reported in cached trials
Duodenal ulcer perforation	3,067	1,385.7 1,327.8–1,446.1ROR 1,924.1 · calibrated p 8e-21 ✓	795.6 EB05 772.2 · IC025 +9.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 519.6 · 93% clinician	not reported in cached trials
C-reactive protein	324	1,069.5 934.4–1,224.0ROR 1,102.0 · calibrated p 1e-17 ✓	656.4 EB05 598.6 · IC025 +8.2 3/3 methods agree	Lab value / disease marker	serious n=324 · 95% clinician	not reported in cached trials
Hand deformity	4,505	1,011.6 980.8–1,043.4ROR 1,717.6 · calibrated p 3e-20 ✓	657.2 EB05 641.2 · IC025 +9.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 466.4 · 93% clinician	not reported in cached trials
Facet joint syndrome	1,068	986.5 918.4–1,059.7ROR 1,093.0 · calibrated p 9e-18 ✓	640.8 EB05 609.2 · IC025 +8.9 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=1,068 · 94% clinician	not reported in cached trials
Hypocholesterolaemia	99	911.8 717.9–1,158.1ROR 920.1 · calibrated p 2e-16 ✓	549.5 EB05 464.5 · IC025 +6.9 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=99 · 98% clinician	not reported in cached trials
Helicobacter infection	2,989	797.9 767.8–829.1ROR 1,096.9 · calibrated p 8e-18 ✓	559.1 EB05 542.5 · IC025 +8.9 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 385.9 · 93% clinician	not reported in cached trials
Adjustment disorder with depressed mood	586	788.0 716.9–866.2ROR 832.5 · calibrated p 2e-16 ✓	546.3 EB05 510.2 · IC025 +8.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=586 · 95% clinician	not reported in cached trials
Retinitis	475	764.6 688.4–849.1ROR 799.2 · calibrated p 4e-16 ✓	532.7 EB05 493.7 · IC025 +8.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=475 · 96% clinician	not reported in cached trials
X-ray abnormal	494	735.6 664.1–814.8ROR 770.3 · calibrated p 6e-16 ✓	518.9 EB05 481.6 · IC025 +8.3 3/3 methods agree	Lab value / disease marker	serious n=494 · 97% clinician	not reported in cached trials
Dislocation of vertebra	605	718.0 655.0–786.9ROR 759.9 · calibrated p 7e-16 ✓	512.0 EB05 478.6 · IC025 +8.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=605 · 94% clinician	not reported in cached trials
Subcutaneous drug absorption impaired	142	677.0 559.4–819.4ROR 685.9 · calibrated p 3e-15 ✓	467.1 EB05 406.1 · IC025 +7.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=142 · 100% clinician	not reported in cached trials
Pericarditis	4,261	660.2 641.0–679.9ROR 1,079.8 · calibrated p 1e-17 ✓	488.3 EB05 476.1 · IC025 +8.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 321.1 · 93% clinician	not reported in cached trials
Muscle injury	2,017	625.9 597.4–655.9ROR 767.0 · calibrated p 5e-16 ✓	468.2 EB05 451.3 · IC025 +8.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 331.6 · 94% clinician	not reported in cached trials
Swollen joint count	60	619.0 462.7–828.1ROR 622.4 · calibrated p 2e-14 ✓	405.9 EB05 326.8 · IC025 +6.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=60 · 92% clinician	not reported in cached trials
Peripheral venous disease	960	607.8 566.6–652.1ROR 666.1 · calibrated p 3e-15 ✓	455.8 EB05 432.2 · IC025 +8.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=960 · 95% clinician	not reported in cached trials
Sleep disorder due to general medical condition, hypersomnia type	24	604.2 381.7–956.4ROR 605.5 · calibrated p 1e-13 ✓	335.4 EB05 237.2 · IC025 +4.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=24 · 92% clinician	not reported in cached trials
Synovitis	4,248	591.3 574.4–608.7ROR 965.2 · calibrated p 4e-17 ✓	449.6 EB05 438.4 · IC025 +8.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 307.0 · 93% clinician	not reported in cached trials
Folliculitis	2,296	548.8 525.9–572.6ROR 694.1 · calibrated p 2e-15 ✓	423.9 EB05 409.6 · IC025 +8.5 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 325.5 · 94% clinician	not reported in cached trials
Seronegative arthritis	249	547.3 475.9–629.4ROR 560.0 · calibrated p 2e-14 ✓	411.1 EB05 370.0 · IC025 +7.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=249 · 94% clinician	not reported in cached trials
Sleep disorder due to general medical condition, insomnia type	1,383	525.2 496.3–555.7ROR 600.9 · calibrated p 8e-15 ✓	408.8 EB05 391.0 · IC025 +8.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=1,382 · 93% clinician	not reported in cached trials
Glossodynia (burning tongue/mouth pain)	4,787	523.1 509.7–536.9ROR 928.4 · calibrated p 6e-17 ✓	409.2 EB05 399.5 · IC025 +8.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 386.0 · 93% clinician	not reported in cached trials
Grip strength	43	436.5 313.4–607.8ROR 438.2 · calibrated p 9e-13 ✓	306.4 EB05 236.9 · IC025 +5.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=43	not reported in cached trials
Wound	4,630	383.3 373.6–393.1ROR 663.1 · calibrated p 3e-15 ✓	318.3 EB05 310.7 · IC025 +8.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 293.8 · serious PRR 246.9 · 94% clinician	not reported in cached trials
Tender joint count	14	377.6 212.8–670.1ROR 378.1 · calibrated p 4e-11 ✓	220.5 EB05 139.6 · IC025 +3.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=14	not reported in cached trials
C-reactive protein abnormal	1,009	358.4 336.0–382.4ROR 394.7 · calibrated p 7e-13 ✓	299.7 EB05 284.5 · IC025 +7.9 3/3 methods agree	Lab value / disease marker	serious n=1,009 · 95% clinician	not reported in cached trials
Acquired porphyria	11	352.0 185.0–669.9ROR 352.4 · calibrated p 1e-10 ✓	196.3 EB05 117.0 · IC025 +3.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=11	not reported in cached trials
Systemic lupus erythematosus	5,337	340.7 333.2–348.4ROR 663.5 · calibrated p 3e-15 ✓	288.5 EB05 282.0 · IC025 +8.1 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 249.7 · serious PRR 192.8 · 93% clinician	not reported in cached trials
Onychomadesis	566	302.3 277.2–329.7ROR 318.7 · calibrated p 6e-12 ✓	258.4 EB05 241.1 · IC025 +7.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=565 · 94% clinician	not reported in cached trials
Breast cancer stage iii	868	298.9 278.9–320.3ROR 324.5 · calibrated p 5e-12 ✓	256.7 EB05 242.7 · IC025 +7.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=868 · 94% clinician	not reported in cached trials
Nail operation	55	295.8 222.8–392.9ROR 297.3 · calibrated p 2e-11 ✓	235.1 EB05 187.4 · IC025 +5.8 3/3 methods agree	Reporting / coding artifact	serious n=55	not reported in cached trials
Contraindicated product administered	3,896	284.3 276.5–292.4ROR 440.7 · calibrated p 2e-13 ✓	246.9 EB05 240.5 · IC025 +7.9 3/3 methods agree	Reporting / coding artifact	age-adj. PRR 225.7 · serious PRR 200.1 · 93% clinician	not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

Concept	Reports	PRR 95% CI	Reading
Liver injury	4,753	30.630.0–31.3	signal
Interstitial lung disease	942	19.017.8–20.2	signal
Hyperglycaemia / diabetes	2,647	14.814.3–15.3	signal
Depression	1,073	7.36.9–7.8	signal
Serious infection	2,846	7.16.9–7.3	signal
Rhabdomyolysis / myopathy	148	3.53.0–4.1	signal
Pancreatitis	126	3.02.5–3.6	signal
Gi bleeding	193	2.01.8–2.3	raised
Fall / fracture	300	1.51.4–1.7	raised
Anaphylaxis / angioedema	95	1.51.2–1.8	raised
Severe cutaneous reaction	48	1.20.9–1.6	no difference
Suicidality	130	1.00.9–1.2	no difference
Thrombocytopenia	102	0.90.7–1.1	no difference
Anaemia	81	0.50.4–0.6	lower than other drugs
Venous thromboembolism	54	0.50.4–0.6	lower than other drugs
Arrhythmia / qt	43	0.40.3–0.6	lower than other drugs

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Pseudoephedrine as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).

NCT01202279 — Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI (N=1179, PHASE4; 4 AE terms posted; arms: Mucinex D; Placebo)

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Systemic lupus erythematosus	5,337	340.7 333.2–348.4ROR 663.5 · calibrated p 3e-15 ✓	288.5 EB05 282.0 · IC025 +8.1 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 249.7 · serious PRR 192.8 · 93% clinician	not reported in cached trials
Pain	5,310	16.7 16.3–17.0ROR 31.4 · calibrated p 2e-4 ✓	16.5 EB05 16.2 · IC025 +4.0 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 13.4 · serious PRR 16.9 · 92% clinician	not reported in cached trials
Drug ineffective (drug did not work)	5,277	7.7 7.6–7.9ROR 13.9 · calibrated p 0.009 ✓	7.7 EB05 7.5 · IC025 +2.9 3/3 methods agree	Reporting / coding artifact	age-adj. PRR 7.6 · serious PRR 13.6	not reported in cached trials
Pemphigus	5,214	1,395.2 1,353.3–1,438.4ROR 2,661.6 · calibrated p 1e-22 ✓	800.4 EB05 782.3 · IC025 +9.5 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 523.9 · 92% clinician	not reported in cached trials
Rheumatoid arthritis	5,213	92.5 90.6–94.4ROR 175.6 · calibrated p 1e-9 ✓	88.2 EB05 86.2 · IC025 +6.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 67.0 · serious PRR 70.2 · 93% clinician	not reported in cached trials
Abdominal discomfort	5,117	60.4 59.2–61.7ROR 112.6 · calibrated p 5e-8 ✓	58.6 EB05 57.3 · IC025 +5.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 49.3 · serious PRR 85.6 · 92% clinician	not reported in cached trials
Alopecia (hair loss)	5,011	50.0 49.0–51.1ROR 91.3 · calibrated p 2e-7 ✓	48.7 EB05 47.6 · IC025 +5.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 37.1 · serious PRR 67.8 · 92% clinician	not reported in cached trials
Glossodynia (burning tongue/mouth pain)	4,787	523.1 509.7–536.9ROR 928.4 · calibrated p 6e-17 ✓	409.2 EB05 399.5 · IC025 +8.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 386.0 · 93% clinician	not reported in cached trials
Fatigue (tiredness)	4,648	11.5 11.3–11.8ROR 19.3 · calibrated p 0.002 ✓	11.5 EB05 11.2 · IC025 +3.5 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 9.0 · serious PRR 14.1 · 91% clinician	not reported in cached trials
Wound	4,630	383.3 373.6–393.1ROR 663.1 · calibrated p 3e-15 ✓	318.3 EB05 310.7 · IC025 +8.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 293.8 · serious PRR 246.9 · 94% clinician	not reported in cached trials
Swelling	4,606	99.3 97.1–101.6ROR 170.7 · calibrated p 2e-9 ✓	94.4 EB05 92.1 · IC025 +6.5 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 76.9 · serious PRR 99.7 · 93% clinician	not reported in cached trials
Rash	4,566	20.4 19.9–20.8ROR 34.2 · calibrated p 1e-4 ✓	20.2 EB05 19.7 · IC025 +4.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	age-adj. PRR 17.4 · serious PRR 29.2 · 92% clinician	not reported in cached trials
Hand deformity	4,505	1,011.6 980.8–1,043.4ROR 1,717.6 · calibrated p 3e-20 ✓	657.2 EB05 641.2 · IC025 +9.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 466.4 · 93% clinician	not reported in cached trials
Pericarditis	4,261	660.2 641.0–679.9ROR 1,079.8 · calibrated p 1e-17 ✓	488.3 EB05 476.1 · IC025 +8.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 321.1 · 93% clinician	not reported in cached trials
Synovitis	4,248	591.3 574.4–608.7ROR 965.2 · calibrated p 4e-17 ✓	449.6 EB05 438.4 · IC025 +8.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 307.0 · 93% clinician	not reported in cached trials

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Pseudoephedrine?

In FDA FAERS, the most frequently co-reported reaction terms for Pseudoephedrine are systemic lupus erythematosus, pain, pemphigus, rheumatoid arthritis, abdominal discomfort, alopecia. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Pseudoephedrine have an FDA boxed warning?

No. The FDA label retrieved for Pseudoephedrine has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Pseudoephedrine causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 09feb5f0-c22d-4a1b-97a0-d5767e5f7730, effective 20241107; matched on openfda.generic_name.exact:"PSEUDOEPHEDRINE HCL")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 976 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath
ClinicalTrials.gov API v2 (query PSEUDOEPHEDRINE, results-bearing studies sorted by enrollment)

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.